MNBTD
BCRX icon

Moody National Bank Trust Division’s BioCryst Pharmaceuticals BCRX Stock Holding History

Moody National Bank Trust Division’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-46,011
Closed -$349K – 508
2025
Q3 		$349K Sell
46,011
-152
-0.3% -$1.27K 0.03% 388
2025
Q2 		$414K Sell
46,163
-11,989
-21% -$112K 0.04% 362
2025
Q1 		$436K Sell
58,152
-2,218
-4% -$17.9K 0.05% 358
2024
Q4 		$454K Hold
60,370
– – 0.05% 356
2024
Q3 		$459K Buy
60,370
+8,324
+16% +$63.3K 0.05% 356
2024
Q2 		$322K Hold
52,046
– – 0.03% 373
2024
Q1 		$264K Hold
52,046
– – 0.02% 407
2023
Q4 		$312K Hold
52,046
– – 0.02% 401
2023
Q3 		$368K Buy
52,046
+9,565
+23% +$68.7K 0.02% 458
2023
Q2 		$299K Buy
42,481
+4,893
+13% +$39.3K 0.02% 512
2023
Q1 		$313K Buy
37,588
+11,867
+46% +$114K 0.03% 498
2022
Q4 		$295K Buy
25,721
+310
+1% +$3.87K 0.03% 491
2022
Q3 		$320K Buy
+25,411
New +$327K 0.03% 442
2019
Q2 		– Sell
-667
Closed -$5K – 430
2019
Q1 		$5K Buy
+667
New +$5.71K ﹤0.01% 862

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Moody National Bank Trust Division's BCRX Position: Q4 2025 in Review

Moody National Bank Trust Division sold out of BioCryst Pharmaceuticals (BCRX) in Q4 2025, closing a stake of 46,011 shares — an estimated $349K sold.

Moody National Bank Trust Division first reported a position in BCRX in Q1 2019 and held it in 14 quarters. The position peaked at $459K in Q3 2024. 273 funds tracked by Wall St. Rank hold BCRX as of Q4 2025.

  • Moody National Bank Trust Division reported no remaining BioCryst Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Moody National Bank Trust Division sold 46,011 BioCryst Pharmaceuticals shares in Q4 2025, an estimated $349K.
  • Moody National Bank Trust Division first reported a position in BioCryst Pharmaceuticals in Q1 2019 and held it in 14 quarters.
  • Moody National Bank Trust Division's BioCryst Pharmaceuticals position peaked at $459K in Q3 2024.
  • 273 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2025.

Based on Moody National Bank Trust Division's 13F filing for Q4 2025, filed 12 Jan 2026.